eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

3/2019
vol. 11
 
Share:
Share:
more
 
 
Original paper

Treatment planning considerations for 125I eye plaque brachytherapy

David Miguel
,
Jesús María de Frutos
,
Francisco López-Lara
,
Pilar Alonso
,
Patricia Diezhandino
,
María Antonia Saornil
,
Ciro García

J Contemp Brachytherapy 2019; 11, 3: 280–284
Online publish date: 2019/06/28
Article file
- Treatment planning.pdf  [1.26 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Purpose

Uveal melanoma is the most frequent primary malignant intraocular tumor in adults, with an annual age-adjusted incidence of 5.1 cases per million [1]. The main clinical goals of brachytherapy are tumor control, eye preservation, maintenance of vision, and quality of life.

The workflow in choroidal melanoma interventional radiotherapy is typically articulated in five main issues: 1) Multidisciplinary tumor board: case presentation and treatment choice; 2) Treatment planning: plan calculation and preplan approval; 3) Source preparation: applicator loading and sterilization; 4) Surgery: plaque implantation, treatment; 5) Plaque removal [2,3,4,5].

Radiation oncologist typically defines clinical target volume (CTV) considering tumor thickness from B-scan sonography images. A safety margin extension of 1-2 mm in all directions surrounding the tumor base [6] that accounts for microscopic extension of the tumor as recommended by the American Brachytherapy Society (ABS) [7], is usually defined as the planning target volume (PTV) [8]. An extra margin can be added by the radiation oncologist in case of doubts in plaque localization or tumor delineation [9].

Plaques are typically positioned under the tumor, and a dose of 85 Gy is usually prescribed to the apex of the tumor as recommended by the ABS [7]. A dose rate of 0.60-1.05 Gy/h delivering a total dose in 3 to 10 consecutive days is suggested [10]. For very posterior localizations, the plaques may be customized with notches of gold rim to allow the placement adjacent to the optic nerve sheath in juxtapapillary tumors.

Calculations are based on the reports of the American Association of Physicists in Medicine Task Group No. 43 [10,11]. In modern brachytherapy planning systems, recently implemented model-based dose calculation algorithms includes tissues heterogeneities. However, any change in the prescribed dose must be carefully verified before the introduction of model-based system into clinical environment [12].

Some authors have developed methods for COMS plaque brachytherapy to select intra-plaque ring radionuclides and source strengths depending on an individual patient to deliver more conformal and more homogeneous tumor dose distributions rather than uniformly-loaded 125I plaque [13] or even modified plaque for iris melanoma [14]. In general, clinical optimization of eye plaque brachytherapy is limited to tumor coverage, consensus prescription dosage, and dose calculations to ocular structures [13].

The severity of disorders (retinopathy, maculopathy, cataract, neovascular glaucoma, and nerve atrophy) before brachytherapy mainly depend on the amount of incidental irradiation of the respective tissues and ocular structures radiosensitivity [15,16,17,18,19,20,21,22]. So, an optimization with reduction of side effects without a loss of local tumor control is essential [23].

The aim of this technical note is to present a series of observations regarding the dosimetry used at our institution in order to reduce the dose to organs at risk and to adjust the treatment time to the needs of the center.

Material and methods

The three-dimensional reconstruction and the dosimetry was performed by a computer system developed by Dr. Astrahan at the University of California (BEBIG plaque simulator, version 2.16) [23]. Calculations were based on the reports of the American Association of Physicists in Medicine Radiation Therapy Committee Task Group No. 43 [10,11] for iodine plaques. Plaque heterogeneity correction functions were incorporated into the treatment planning, and the dose collimation by the gold-alloy backing and the global attenuation factor with the effect of eye plaque seed carrier were also included [24].

In dosimetry planning using 125I seeds applicator, there are three main factors to be considered: distance to organs at risk, source strength of seeds, and geometry of plaque.

Results

Distance to organs at risk

The distance of the applicator to organs at risk is perhaps the most important factor, since the dose presents a diminishment proportionally to the inverse of the square of the distance. Thus, the appropriate distance without sacrificing the tumor margins is able to protect (to a certain extent) the organ at risk. Although the plaques are typically placed under the tumor, it is permissible to slightly change their position in order to avoid critical structures (macula or optic nerve) without compromising the correct coverage of the tumor (Table 1) [25,26,27].

Table 1

Treatments features from our institution and other series of patients treated with episcleral brachytherapy, mean values. Seed Amersham model 6711 and Bebig model I25.S16 are used for ROPES and COMS plaques, respectively

Shields [25] N = 1300Melia [26] N = 623Gündüz [27] N = 630Our institution N = 247
Radionuclide125I125I106Ru125I
Treatment time (h)120.6141.2120.0129.50
Dose rate (cGy/h)70.580.080.069.5
Dose to tumor apex (Gy)85.095.291.285.31
Dose to optic nerve (Gy)52.170.659.036.30
Dose to lens (Gy)15.624.111.719.36
Dose to foveola/macula (Gy)79.086.9122.151.8
Dose to sclera (Gy)*294.15

* 1 mm from plaque center

Mixture of sources

A mixture of sources of different source strengths can optimize the distribution of isodose and protect organs without sacrificing margins of the tumor (Table 1). Similarly, due to limited availability of an operating room (i.e., twice a week, only in the morning, etc.), the use of seeds with different reference of air kerma strength (RAKR) can modify the treatment time to adjust to accessibility of operating room. It does not influence the correct coverage of the tumor.

Finally, for mushroom-shaped tumors with much bigger height than the base, an optimal strategy is to load the plate with seeds of higher source strength in the center and with seeds of fewer source strength at the edges of tumor.

Geometry of the applicator

For each 125I seed, the geometry function in dose calculation formalism provides an inverse square-law correction based on approximate model of the spatial distribution of activity in the source, neglecting scattering and attenuation. As in anisotropy, the sources may be oriented in such a way that their ends are directed at the organ at risk, since the self-absorption of the source is notable at these points and the dose falloff can be remarkable.

The seed carriers of the plaques can be manually rotated within the shell, so that a roughly elliptically shaped subset of the seed positions in the carrier would spatially conform to the shape of the tumor base and margin without over irradiating organs at risk (Table 1). The plaques can also be rotated to balance the distance of the suture eyelets from the limbus to simplify the surgery. In investigated case, the dosimetric differences were moderate during rotation of the seed carrier.

Discussion

In the study (Figure 1), a reduction of dose to the macula and optic disk was observed from 62 Gy and 52 Gy, to 45 Gy and 40 Gy, respectively, while maintaining dosimetric coverage of the tumor. The optimization of treatment time has an immediate effect on availability of operating rooms at hours that are convenient for our institution, and this is important circumstance from the logistic point of view.

Fig. 1

Different plans according to the points of improvement. Tumor with a circular size of 11 mm of diameter and 5 mm of height is presented. The COMS plaque diameter is 16 mm. The first row is a plan without any consideration. Dose to critical structures and treatment time (operating room is available preferably in the mornings) clearly improving. Next row shows a big improvement by separating the plaque from organs at risk. Next row presents a mixture of seeds to adjust the treatment time. Next row shows how the seed carrier rotates into the plaque with a little improvement of the dose to macula. The last row is the final plan of treatment; it is a combination of all techniques described. The time of insertion was always the same: Monday 21/01/2019 at 9:30 am

/f/fulltexts/JCB/37095/JCB-11-37095-g001_min.jpg

It is worth to mention that the techniques were used previously at our institution, and there was no difference in either both local tumor control [4] or complications [3,5]. Moreover, for many side effects, the results were better for patients treated at our institution [3,4,5]. Table 1 shows a systematic reduction of the dose to fovea and optic nerve in our institution compared with other centers and radionuclides.

At our institution, new seeds arrive with the frequency of two months. Once a new order is received, the oldest sources are discarded and only sources of less than 6 months old remain for use. From the therapeutic point of view, three sets of seeds are sufficient for an optimal personalized dosimetry. Therefore, the availability of different radionuclides and their possible combined use for 125I applicators shows a significant progress in dosimetry, as found in other studies [28,29,30].

According to our quality assurance protocol, the seed lots are stored in separate compartments. Before and after the assembly of the plaque, the RAKR of each seed is confirmed with a well counter. The verification of the correct source strengths and assembly is conducted by two dosimetrists.

Conclusions

In this paper, we present the different options for an optimization of episcleral brachytherapy regarding the doses and treatment plans. The implementation of these techniques can be of great support for an institution to optimize the resources of brachytherapy unit. The aforementioned strategies have been used at our institution with great success, and no decrease in local control nor an increase in toxicity have been noted.

Acknowledgment

The authors would like to thank the referees for the valuable comments on our manuscript.

Disclosure

Authors report no conflict of interest.

References

1 

Singh AD, Turell ME, Topham AK , authors. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011. 118:p. 1881–1885

2 

Tagliaferri L, Pagliara MM, Boldrini L, et al. , authors. INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures. J Contemp Brachytherapy. 2017. 9:p. 287–295

3 

Miguel D, de Frutos-Baraja JM, López-Lara F, et al. , authors. Radiobiological doses, tumor, and treatment features influence on outcomes after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II. J Contemp Brachytherapy. 2018. 10:p. 347–359

4 

Miguel D, de Frutos-Baraja JM, López-Lara F, et al. , authors. Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I. J Contemp Brachytherapy. 2018. 10:p. 337–346

5 

Miguel D, de Frutos-Baraja JM, López-Lara F, et al. , authors. Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses. J Contemp Brachytherapy. 2018. 10:p. 123–131

6 

ICRU , author. Dosimetry of Beta rays and low-energy photons for brachytherapy with sealed sources: contents. J ICRU. 2004. 4:p. 5–8

7 

Nag S, Quivey JM, Earle JD, et al. , authors. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003. 56:p. 544–555

8 

Damato B , author. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye (Lond). 2012. 26:p. 1157–1172

9 

Gagne NL, Rivard MJ , authors. Quantifying the dosimetric influences of radiation coverage and brachytherapy implant placement uncertainty on eye plaque size selection. Brachytherapy. 2013. 12:p. 508–520

10 

Rivard MJ, Coursey BM, DeWerd LA, et al. , authors. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004. 31:p. 633–674

11 

Nath R, Anderson LL, Luxton G, et al. , authors. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995. 22:p. 209–234

12 

Poder J, Corde S , authors. I-125 ROPES eye plaque dosimetry: Validation of a commercial 3D ophthalmic brachytherapy treatment planning system and independent dose calculation software with GafChromic® EBT3 films. Med Phys. 2013. 40:p. 121709

13 

Gagne NL, Cutright DR, Rivard MJ , authors. Keeping an eye on the ring: COMS plaque loading optimization for improved dose conformity and homogeneity. J Contemp Brachytherapy. 2012. 4:p. 165–175

14 

Scanderbeg DJ, Vasudev D, Rice RK, et al. , authors. A modified COMS plaque for iris melanoma. J Contemp Brachytherapy. 2011. 3:p. 131–133

15 

Parsons JT, Bova FJ, Mendenhall WM, et al. , authors. Response of the normal eye to high dose radiotherapy. Oncology. 1996. 10:p. 837–847

16 

Gündüz K, Shields CL, Shields JA, et al. , authors. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol. 1999. 117:p. 609–614

17 

Fontanesi J, Meyer D, Xu S, et al. , authors. Treatment of choroidal melanoma with 125I plaque. Int J Radiat Oncol Biol Phys. 1993. 26:p. 619–623

18 

Lommatzsch PK , author. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas. Twenty years’ experience. Am J Clin Oncol. 1987. 10:p. 146–151

19 

Summanen P, Immonen I, Kivela T, et al. , authors. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol. 1996. 80:p. 732–739

20 

Groenewald C, Konstantinidis L, Damato B , authors. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye (Lond). 2013. 27:p. 163–171

21 

Tagliaferri L, Pagliara MM, Masciocchi C, et al. , authors. Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma. J Contemp Brachytherapy. 2017. 9:p. 540–547

22 

Rospond-Kubiak I, Wróblewska-Zierhoffer M, Twardosz- Pawlik H , authors. Ruthenium brachytherapy for uveal melanoma – single institution experience. J Contemp Brachytherapy. 2017. 9:p. 548–552

23 

Astrahan MA, Luxton G, Jozsef G, et al. , authors. An interactive treatment planning system for ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys. 1990. 18:p. 679–687

24 

Chiu-Tsao S-T, Astrahan MA, Finger PT, et al. , authors. Dosimetry of 125I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS. Med Phys. 2012. 39:p. 6161–6184

25 

Shields CL, Shields JA, Cater J, et al. , authors. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000. 118:p. 1219–1228

26 

Melia BM, Abramson DH, Albert DM, et al. , authors. Collaborative ocular melanoma study (COMS) randomized trial of 125I brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001. 108:p. 348–366

27 

Gündüz K, Shields CL, Shields JA, et al. , authors. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol. 1999. 127:p. 579–589

28 

Chen Z, Nath R , authors. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives. Int J Radiat Oncol Biol Phys. 2003. 55:p. 825–834

29 

Gagne NL, Leonard KL, Rivard MJ , authors. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function. Med Phys. 2012. 39:p. 3332–3342

30 

Rivard MJ, Melhus CS, Sioshansi S, et al. , authors. The impact of prescription depth, dose rate, plaque size, and source loading on the central axis using 103Pd, 125I, and 131Cs. Brachytherapy. 2008. 7:p. 327–335

Copyright: © 2019 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe